30 results about "Hydroxytryptophol" patented technology

The invention relates to bifidobacterium breve CCFM1025, a fermented food and application thereof. The bifidobacterium breve CCFM1025 can be used for improving the depression-like behavior of a depression mouse, improving 5-hydroxytryptamine in the brain of the depression mouse, improving the level of 5-hydroxytryptamine and a brain-derived neurotrophic factor, reducing the level of corticosteronein serum of the depression mouse, improving the level of 5-hydroxytryptamine in the serum of the depression mouse, improving intestinal flora disturbance of the depression mouse, reducing the abundance of intestinal veillonella, improving the abundance of bifidobacterium and mycoplasmataceae, improving alpha-diversity of intestinal flora and reducing occurrence of inflammatory bowel disease and obesity. By adopting the bifidobacterium breve CCFM1025, the mRNA level of tryptophan hydroxylase in a simulated entero-chromaffin cell can be improved, the secretion volume of 5-hydroxytryptophane ofthe cell can be improved, and a precursor substance is specifically provided to synthesis of 5-hydroxytryptamine in the brain. The bifidobacterium breve CCFM1025 has a wide application prospect.

The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor. The present invention provides a pharmaceutical composition comprising (i) a serotonin reuptake inhibitor and (ii) 5-hydroxytrytophan. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to about 75 mg; and (ii) a serotonin reuptake inhibitor. The present invention also provides a pharmaceutical composition comprising (i) a subclinical dose of a serotonin reuptake inhibitor; and (ii) 5-hydroxytryptophan.

5-hydroxytryptophan (5-HTP), a precursor of serotonin, is produced in a microbial host cell. A modified bacterial phenylalanine 4-hydroxylase (P4H) catalyzes the tryptophan 5-hydroxylation reaction. Optionally the host cell includes a cofactor regeneration mechanism, allowing continuous production of 5-HTP without supplementation of exogenous cofactors.

The present invention provides a composition for use as a medicament, the composition comprising a cell of a recombinant microorganism, the cell being capable of producing an increased amount of one or more of 5-hydroxytryptophan (5-HTP), 5-hydroxytryptamine (5-HT) and tryptamine (TRM) compared to a non-recombinant microorganism from which the cell is derived. The composition can be used for preventing and/or treating TRM, 5-HTP or 5-HT related conditions in mammals: central nervous system (CNS) conditions; an enteral nervous system (ENS) disorder; gastrointestinal (GI) disorders and metabolic disorders, and the compositions can be orally administered to mammals in need thereof. Furthermore, a composition comprising cells of a recombinant microorganism capable of producing melatonin is provided for use as a medicament, such as for the treatment of depression, dementia, cancer and sleep disorders.

The invention discloses an engineering strain for synthesizing serotonin by using 5-hydroxytryptophan as a substrate microorganism as well as construction and application of the engineering strain, and belongs to the technical field of biology. The engineering strain contains a 5-hydroxytryptophan decarboxylase gene, and 5-hydroxytryptophan is finally catalyzed to generate serotonin through expression in a host strain. The method is simple to operate, free of environmental pollution, high in yield, high in purity and low in cost, a basis is provided for industrial production of the serotonin, and the highest yield of the final product serotonin can reach 31.9 g/L.

The invention discloses a composition for preventing and treating female physiological cycle disorder caused by plateau hypoxia and application. The composition is prepared from, by mass, 24 parts of radix astragali extract, 16 parts of poria cocos extract, 18 parts of caulis polygoni multiflori extract, 21 parts of radix codonopsis extract, 8 parts of radix angelicae sinensis extract, 11 parts of radix salviae miltiorrhizae extract and 2 parts of 5-hydroxytryptophan. Experiments prove that the composition disclosed by the invention can remarkably prolong the normal-pressure closed hypoxia survival time of female mice and can remarkably improve female physiological cycle disorder caused by plateau hypoxia exposure.

The invention belongs to the technical field of food processing, and discloses soda water with a flos sophorae flavor and a preparation method thereof. The soda water is prepared from, by mass, 3.0% of sodium bicarbonate, 0.2% of flos sophorae essence, 0.3% of an African griffonia simplicifolia seed extract and 96.5% of water. The method is simple in process and low in cost, and equipment used inthe preparation process is disinfected by ozone to ensure water safety; the soda water is cool and sweet in taste after beingdrunk and weakly alkaline, and the balance of sodium and potassium in the body can be adjusted; the flos sophorae essence serves as a flos sophorae flavor regulator, and the taste is fresh, sweet and consistent with that of a soda water base and additives; existing lemon, rose and mint flavors in the market are enriched, and the consumption demands of the public are met; the main active ingredient of the African griffonia simplicifolia seed extract added in the formula is 5-hydroxytryptophan (5-HT), and it is shown through pharmacological studies that the soda water has the effects of increasing the 5-HT concentration in the brain, inhibiting depression, promoting melatonin synthesis and improving sleep quality.

The invention provides a quantitative analysis method for biogenic amine neurotransmitters, and relates to the technical field of detection. According to the quantitative analysis method for the biogenic amine neurotransmitters, a sample is pretreated, and then the biogenic amine neurotransmitters in the sample are quantitatively analyzed by adopting a liquid chromatography-tandem mass spectrometry method. The pretreatment comprises derivatization and internal reference addition; the biogenic amine neurotransmitter is prepared from the following components: 3-methoxy-4-hydroxy-phenyl glycol, 5-hydroxytryptamine, dopamine, 3-methoxytyrosine, noradrenaline, epinephrine, methylephrine, noradrenaline, homovanillic acid, 5-hydroxyindoleacetic acid, dopa, 3-methoxydopa, vanillic mandelic acid, dihydroxyphenylacetic acid, 5-hydroxytryptophan and vanillic acid. The quantitative analysis method provided by the invention is small in required sample amount, simple, efficient, good in repeatability, low in detection cost and high in sensitivity.

The invention provides a 5-hydroxytryptophan transporter which has an amino acid sequence as shown in SEQ ID No.1. The invention also provides a method for modifying a 5-hydroxytryptophan production bacterium to realize high yield, and the method is characterized in that the transporter as shown in SEQ ID No.1 is over-expressed in a host of the 5-hydroxytryptophan production bacterium.